Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


European spongiform risk materials 18-month phase-out recommended by CPMP.

This article was originally published in The Rose Sheet

Executive Summary

EUROPEAN SPONGIFORM RISK MATERIALS 18-MONTH PHASE-OUT RECOMMENDED by the Committee on Proprietary Medicinal Products in a "provisional report" released after the group's meeting Oct. 20-23. "For products manufactured using derivatives of [specified risk materials], or other bovine-derived materials used as reagents, it would take manufacturers well into 1999 to change their production eliminate the use of such materials," the committee noted. "Hence, a substantial transition period of at least 18 months should be provided for any necessary changes." Therefore, European restrictions on use of such products should be applied prospectively after Jan. 1, and not retroactively to existing products without a suitable transition period, CPMP advised.



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts